{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:52:25Z","timestamp":1783511545980,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","award":["HA21C0110"],"award-info":[{"award-number":["HA21C0110"]}],"id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Korea Ministry of Health and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ajt.2025.01.005","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T07:49:13Z","timestamp":1737186553000},"page":"1285-1295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Association between everolimus combination therapy and cancer risk after liver transplantation: A nationwide population-based quasi-cohort study"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6220-7635","authenticated-orcid":false,"given":"Suk-Chan","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5002-0822","authenticated-orcid":false,"given":"Gi-Ae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1544-577X","authenticated-orcid":false,"given":"Young-Suk","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9091-8787","authenticated-orcid":false,"given":"Hye-Lin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0601-7754","authenticated-orcid":false,"given":"Eui-Kyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ajt.2025.01.005_bib1","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2015.10.006","article-title":"Electronic address: easloffice@easloffice.eu. EASL Clinical Practice Guidelines: liver transplantation","volume":"64","year":"2016","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.ajt.2025.01.005_bib2","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1053\/j.gastro.2010.01.030","article-title":"Current and future trends in liver transplantation in Europe","volume":"138","author":"Dutkowski","year":"2010","journal-title":"Gastroenterology"},{"issue":"suppl 3","key":"10.1016\/j.ajt.2025.01.005_bib3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/lt.22410","article-title":"Present state of immunosuppressive therapy in liver transplant recipients","volume":"17","author":"Wiesner","year":"2011","journal-title":"Liver Transpl"},{"issue":"2","key":"10.1016\/j.ajt.2025.01.005_bib4","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.ajt.2025.01.005_bib5","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/j.1600-6143.2012.04212.x","article-title":"Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial","volume":"12","author":"De Simone","year":"2012","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.ajt.2025.01.005_bib6","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/ajt.12280","article-title":"Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study","volume":"13","author":"Saliba","year":"2013","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.ajt.2025.01.005_bib7","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/TP.0000000000000555","article-title":"Three-year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus: follow-up results from a randomized, multicenter study","volume":"99","author":"Fischer","year":"2015","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.ajt.2025.01.005_bib8","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/apt.15253","article-title":"Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma","volume":"49","author":"Grigg","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.ajt.2025.01.005_bib9","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/lt.20391","article-title":"Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression","volume":"11","author":"Vivarelli","year":"2005","journal-title":"Liver Transpl"},{"issue":"5","key":"10.1016\/j.ajt.2025.01.005_bib10","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/SLA.0b013e3181896278","article-title":"Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence","volume":"248","author":"Vivarelli","year":"2008","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.ajt.2025.01.005_bib11","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1001\/jamadermatol.2015.5548","article-title":"Hills VM, Schmults CD. Association of sirolimus use with risk for skin cancer in a mixed-organ cohort of solid-organ transplant recipients with a history of cancer","volume":"152","author":"Karia","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"8","key":"10.1016\/j.ajt.2025.01.005_bib12","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/ndt\/gfw088","article-title":"Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients","volume":"31","author":"Opelz","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.ajt.2025.01.005_bib13","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/ajt.12615","article-title":"Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation","volume":"14","author":"Sterneck","year":"2014","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.ajt.2025.01.005_bib14","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/ajt.14623","article-title":"Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study","volume":"18","author":"Jeng","year":"2018","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.ajt.2025.01.005_bib15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3350\/cmh.2021.0038","article-title":"Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma","volume":"27","author":"Kang","year":"2021","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"10.1016\/j.ajt.2025.01.005_bib16","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/EDE.0000000000000221","article-title":"The Quasi-cohort approach in pharmacoepidemiology: upgrading the nested case-control","volume":"26","author":"Suissa","year":"2015","journal-title":"Epidemiology"},{"issue":"1","key":"10.1016\/j.ajt.2025.01.005_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0168-8510(94)00669-6","article-title":"Health for all in the Republic of Korea: one country\u2019s experience with implementing universal health care","volume":"31","author":"Peabody","year":"1995","journal-title":"Health Policy"},{"issue":"6","key":"10.1016\/j.ajt.2025.01.005_bib18","doi-asserted-by":"crossref","first-page":"398","DOI":"10.7326\/M18-3079","article-title":"Graphical depiction of longitudinal study designs in health care databases","volume":"170","author":"Schneeweiss","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ajt.2025.01.005_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.906211","article-title":"Optimal indicator of death for using real-world cancer patients' data from the healthcare system","volume":"13","author":"Jang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.ajt.2025.01.005_bib20","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1053\/jlts.2003.50101","article-title":"Rapamycin: friend, foe, or misunderstood?","volume":"9","author":"Fung","year":"2003","journal-title":"Liver Transpl"},{"issue":"12","key":"10.1016\/j.ajt.2025.01.005_bib21","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.2337\/dc12-0788","article-title":"Metformin and the risk of cancer: time-related biases in observational studies","volume":"35","author":"Suissa","year":"2012","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.ajt.2025.01.005_bib22","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/pds.5083","article-title":"Time-related biases in pharmacoepidemiology","volume":"29","author":"Suissa","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"345","key":"10.1016\/j.ajt.2025.01.005_bib23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/01621459.1974.10480131","article-title":"Evaluation of response-time data involving transient states: an illustration using heart-transplant data","volume":"69","author":"Mantel","year":"1974","journal-title":"J Am Stat Assoc"},{"issue":"26","key":"10.1016\/j.ajt.2025.01.005_bib24","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1002\/sim.7019","article-title":"Use of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation study","volume":"35","author":"Mi","year":"2016","journal-title":"Stat Med."},{"issue":"4","key":"10.1016\/j.ajt.2025.01.005_bib25","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jhep.2018.12.009","article-title":"Age and liver transplantation","volume":"70","author":"Durand","year":"2019","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.ajt.2025.01.005_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1214\/09-STS313","article-title":"Matching methods for causal inference: a review and a look forward","volume":"25","author":"Stuart","year":"2010","journal-title":"Stat Sci"},{"issue":"6","key":"10.1016\/j.ajt.2025.01.005_bib27","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.annonc.2021.02.014","article-title":"Electronic address: clinicalguidelines@esmo.org; ESMO Guidelines Committee. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines","volume":"32","author":"Vogel","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ajt.2025.01.005_bib28","doi-asserted-by":"crossref","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","article-title":"Hepatobiliary cancers. version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.ajt.2025.01.005_bib29","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/bcpt.12946","article-title":"Considerations for pharmacoepidemiological studies of drug-cancer associations","volume":"122","author":"Potteg\u00e5rd","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.ajt.2025.01.005_bib30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jclinepi.2016.03.003","article-title":"The lag-time approach improved drug-outcome association estimates in presence of protopathic bias","volume":"78","author":"Arf\u00e8","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"32","key":"10.1016\/j.ajt.2025.01.005_bib31","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1200\/JCO.2017.73.4491","article-title":"Long-term use of long-acting insulin analogs and breast cancer incidence in women with type 2 diabetes","volume":"35","author":"Wu","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7168","key":"10.1016\/j.ajt.2025.01.005_bib32","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1136\/bmj.317.7168.1309","article-title":"Confidence intervals for the number needed to treat","volume":"317","author":"Altman","year":"1998","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.ajt.2025.01.005_bib33","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/lt.22292","article-title":"Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis","volume":"17","author":"Saliba","year":"2011","journal-title":"Liver Transpl"},{"issue":"5","key":"10.1016\/j.ajt.2025.01.005_bib34","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"6","key":"10.1016\/j.ajt.2025.01.005_bib35","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ajt.2025.01.005_bib36","series-title":"Primer of Applied Regression & Analysis of Variance","author":"Glantz","year":"2001"},{"issue":"8","key":"10.1016\/j.ajt.2025.01.005_bib37","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","article-title":"Current development of mTOR inhibitors as anticancer agents","volume":"5","author":"Faivre","year":"2006","journal-title":"Nat Rev Drug Discov."},{"issue":"1","key":"10.1016\/j.ajt.2025.01.005_bib38","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/TP.0000000000000965","article-title":"Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial","volume":"100","author":"Geissler","year":"2016","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.ajt.2025.01.005_bib39","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/lt.26387","article-title":"Sirolimus or everolimus improves survival after liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"28","author":"Yan","year":"2022","journal-title":"Liver Transpl"},{"issue":"6","key":"10.1016\/j.ajt.2025.01.005_bib40","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jhep.2013.07.012","article-title":"Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma","volume":"59","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2013","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.ajt.2025.01.005_bib41","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1111\/ajt.17021","article-title":"Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation","volume":"22","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2022","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.ajt.2025.01.005_bib42","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/archsurg.2007.39","article-title":"Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators","volume":"143","author":"Zimmerman","year":"2008","journal-title":"Arch Surg"},{"issue":"2","key":"10.1016\/j.ajt.2025.01.005_bib43","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/ajt.15697","article-title":"Liver transplantation for hepatocellular carcinoma: management after the transplant","volume":"20","author":"Verna","year":"2020","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.ajt.2025.01.005_bib44","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jhep.2018.12.029","article-title":"Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation","volume":"70","author":"Goldaracena","year":"2019","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.ajt.2025.01.005_bib45","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.3390\/jcm10081558","article-title":"Effect of mycophenolate mofetil therapy on recurrence of hepatocellular carcinoma after liver transplantation: a population-based cohort study","volume":"10","author":"Tsai","year":"2021","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.ajt.2025.01.005_bib46","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/TP.0000000000002647","article-title":"Suppression of hepatocellular carcinoma by mycophenolic acid in experimental models and in patients","volume":"103","author":"Chen","year":"2019","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.ajt.2025.01.005_bib47","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S2468-1253(22)00050-4","article-title":"Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review","volume":"7","author":"Alberts","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S160061352500005X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S160061352500005X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T01:41:40Z","timestamp":1780278100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S160061352500005X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S160061352500005X"],"URL":"https:\/\/doi.org\/10.1016\/j.ajt.2025.01.005","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between everolimus combination therapy and cancer risk after liver transplantation: A nationwide population-based quasi-cohort study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajt.2025.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}